STRATA Skin Sciences (SSKN) 10-Q 14 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'MELA	'
Entity Registrant Name	'MELA SCIENCES, INC. /NY	'
Entity Central Index Key	'0001051514	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	6,037,232

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets:	'	'
Cash and cash equivalents	$14,466,227	$3,782,881	[1]
Accounts receivable (net of allowance of $43,080 and $46,130 as of September 30, 2014 and December 31, 2013, respectively)	85,230	57,151	[1]
Inventory (net of reserves of $1,401,333 as of September 30, 2014 and $325,000 as of December 31, 2013, respectively)	5,363,787	5,631,205	[1]
Prepaid expenses and other current assets	617,185	879,698	[1]
Total Current Assets	20,532,429	10,350,935	[1]
Property and equipment, net	2,713,083	3,690,784	[1]
Patents and trademarks, net	37,988	41,795	[1]
Deferred financing costs	981,950	'
Other assets	48,000	48,000	[1]
Total Assets	24,313,450	14,131,514	[1]
Current Liabilities:	'	'
Accounts payable (includes related parties of $70,711 and $32,902 as of September 30, 2014 and December 31, 2013, respectively)	1,271,877	1,478,995	[1]
Accrued expenses (includes related parties of $0 and $48,000 as of September 30, 2014 and December 31, 2013, respectively)	1,010,666	844,131	[1]
Deferred placement revenue	85,278	243,605	[1]
Warrant liability	1,451,121	3,017,142	[1]
Other current liabilities	134,072	67,934	[1]
Total Current Liabilities	3,953,014	5,651,807	[1]
Long-Term Liabilities:	'	'
Deferred placement revenue	13,725	63,754	[1]
Deferred rent	90,093	120,120	[1]
Senior secured convertible debentures, (net of discount of $9,967,564 and $0 as of September 30, 2014 and December 31, 2013, respectively)	5,032,441	'
Total Long-Term Liabilities	5,136,259	183,874	[1]
Total Liabilities	9,089,273	5,835,681	[1]
COMMITMENTS AND CONTINGENCIES	'	'	[1]
Stockholders' Equity:	'	'
Preferred stock - $0.10 par value; authorized 10,000,000 shares: issued and outstanding: 12,300 at September 30, 2014 and 0 at December 31, 2013, respectively	1,230	'
Common stock - $0.001 par value; authorized 50,000,000 shares: issued and outstanding 5,217,742 shares at September 30, 2014 and 4,750,160 at December 31, 2013, respectively	5,218	4,750	[1]
Additional paid-in capital	193,007,017	176,438,961	[1]
Accumulated deficit	-177,789,288	-168,147,878	[1]
Total Stockholders' Equity	15,224,177	8,295,833	[1]
Total Liabilities and Stockholders' Equity	$24,313,450	$14,131,514	[1]
[1]	Derived from the audited balance sheet as of December 31, 2013

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Allowance for accounts receivable, current	$43,080	$46,130	[1]
Inventory reserves	1,401,333	325,000	[1]
Accounts payable, related parties	70,711	32,902	[1]
Accrued expenses, related parties	0	48,000	[1]
Senior secured convertible debentures, discount	$9,967,564	$0	[1]
Preferred stock, par value	$0.10	$0.10	[1]
Preferred stock, shares authorized	10,000,000	10,000,000	[1]
Preferred stock, shares issued	12,300	0	[1]
Preferred stock, shares outstanding	12,300	0	[1]
Common stock, par value	$0.00	$0.00	[1]
Common stock, shares authorized	50,000,000	50,000,000	[1]
Common stock, shares issued	5,217,742	4,750,160	[1]
Common stock, shares outstanding	5,217,742	4,750,160	[1]
[1]	Derived from the audited balance sheet as of December 31, 2013

Condensed_Statements_of_Operat

Condensed Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Net revenues	$217,902	$107,707	$540,695	$396,206
Cost of revenue	1,559,502	1,976,501	3,755,086	4,438,211
Gross Profit	-1,341,600	-1,868,794	-3,214,391	-4,042,005
Operating expenses:	'	'	'	'
Research and development	344,525	856,764	1,422,997	3,241,727
Selling, general and administrative	2,314,712	3,480,689	8,353,793	12,440,457
Total operating expenses	2,659,237	4,337,453	9,776,790	15,682,184
Operating Loss	-4,000,837	-6,206,247	-12,991,181	-19,724,189
Other income (expenses):	'	'	'	'
Interest income	3,874	2,508	5,180	7,323
Interest expense	-530,542	-222,758	-532,899	-563,143
Change in fair value of warrant liability	2,108,106	'	7,150,886	-89,859
Write-off of unamortized loan costs	'	-983,330	'	-983,330
Gain on sale of fixed assets	11,000	'	15,740	'
Registration rights liquidated damages	'	'	-3,419,698	'
Other income, net	120,537	5,400	130,562	15,400
Total Other Income/(Loss)	1,712,975	-1,198,180	3,349,771	-1,613,609
Net Loss	($2,287,862)	($7,404,427)	($9,641,410)	($21,337,798)
Basic net loss per common share	($0.44)	($1.72)	($1.89)	($5.10)
Diluted net loss per common share	($0.44)	($1.72)	($1.89)	($5.10)
Basic weighted average number of common shares outstanding	5,216,290	4,312,118	5,108,418	4,182,814
Diluted weighted average number of common shares outstanding	5,216,290	4,312,118	5,108,418	4,182,814

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2014		Sep. 30, 2013
Cash flows from operating activities:	'		'
Net loss	($9,641,410)		($21,337,798)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Write-off of unamortized loan costs	'		983,330
Depreciation and amortization	1,370,802		1,790,037
Impairment of long-lived assets	'		1,010,712
Bad debt expense	700		52,097
Write-off of unamortized financing costs	'		41,166
Stock-based compensation	447,295		1,256,754
Amortization of deferred financing costs	37,689		163,569
Inventory reserves	1,076,333		325,000
Change in fair value of warrant liability	-7,150,886		89,859
Amortization of debt discount	385,359		'
Gain on sale of fixed assets	-15,740		'
Changes in operating assets and liabilities:	'		'
Accounts receivable	-28,779		76,944
Inventory	-1,362,391		79,014
Melafind® systems sold	162,922		'
Prepaid expenses and other current assets	262,513		300,528
Other assets	'		4,000
Accounts payable and accrued expenses	-40,583		-503,345
Other current liabilities	66,138		17,017
Deferred revenue	-208,356		69,364
Deferred rent	-30,027		-17,739
Long-term interest payable	'		86,042
Net cash used in operating activities	-14,668,421		-15,513,449
Cash flows from investing activities:	'		'
Purchases of property and equipment	'		-4,865,358
Proceeds from the sale of fixed assets	17,000		'
Net cash provided by (used in) investing activities	17,000		-4,865,358
Cash flows from financing activities:	'		'
Net proceeds from private placements/public offerings	11,457,831		15,789,873
Proceeds from long-term debt	15,000,005		6,000,000
Expenses related to borrowings and issuance of warrant	-1,123,069		-245,358
Repayment of long-term debt	'		-6,425,000
Proceeds from exercise of stock options	'		18,059
Net cash provided by financing activities	25,334,767		15,137,574
Net increase/(decrease) in cash and cash equivalents	10,683,346		-5,241,233
Cash and cash equivalents at beginning of period	3,782,881	[1]	7,861,524
Cash and cash equivalents at end of period	14,466,227		2,620,291
Non-cash investing and financing activity:	'		'
Reclassification of warrant liability to stockholders' equity	'		652,442
Recognition of debt discount on long-term debt	5,787,573		'
Recognition of beneficial conversion feature on long-term debt	4,565,350		'
Exchange of series A convertible preferred stock for series B convertible preferred stock	$12,300,000		'
[1]	Derived from the audited balance sheet as of December 31, 2013

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Organization and Basis of Presentation	'
	1. ORGANIZATION AND BASIS OF PRESENTATION
	The accompanying unaudited condensed financial statements of MELA Sciences, Inc., a Delaware corporation (“MELA” or the “Company”), have been prepared in accordance with the instructions to Form 10-Q and therefore do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States (“GAAP”); however, such information reflects all adjustments (consisting solely of normal recurring adjustments) that are, in the opinion of management, necessary for a fair statement of the results for the interim periods.
	The condensed financial statements should be read in conjunction with the consolidated financial statements and notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. In addition, some of the Company’s statements in this Quarterly Report on Form 10-Q may involve risks and uncertainties that could significantly impact expected future results. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of results to be expected for the full year.
	The Company is a medical technology company dedicated to designing and developing innovative software-driven technology for the clinical early detection and prevention of skin cancer. The Company is primarily focused on the commercialization of its flagship product, the MelaFind® system, and the further design and development of MelaFind® and its technology. The MelaFind® system is an optical diagnostic device that assists dermatologists in the diagnosis of melanoma. It features a hand-held component that uses light of differing wavelengths to capture digital data from clinically atypical pigmented skin lesions. The data are then analyzed utilizing sophisticated classification algorithms that have been “trained” and blind tested on the Company’s proprietary database of melanomas and benign lesions. The MelaFind® system then provides images and objective data on the relative disorganization of a lesion’s structure that provides substantial additional perspective to assist physicians in the clinical management decision for atypical pigmented skin lesions, including information useful in the decision whether to biopsy the lesion.
	In November 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) for the MelaFind® Pre-Market Approval (“PMA”) application and in September 2011 received Conformite Europeenne (“CE”) Mark approval. In March 2012, the Company installed the first commercial MelaFind® systems, and proceeded with the commercial launch of MelaFind®. The Company is currently conducting a Post-Approval Study (“PAS”) evaluating the sensitivity and false positive rate of physicians after using the MelaFind® system with their performance if MelaFind® was not available.
	The launch of MelaFind® in 2012 and the subsequent commercialization activities supporting the launch did not meet the Company’s initial goals and objectives. Revenues were lower than forecasted and expenses continued to increase throughout 2012 and into 2013. In the third quarter of 2013, a significant cost reduction program was put into place. In November 2013, the Company adopted a refocused “Go-to-Market” strategy concentrating on key institutions, opinion leaders and dermatologists who treat many of the patients at high risk for melanoma. The Company also changed its business model for the MelaFind® system from a rental-based to a sales-based model. The Company has reduced its costs, added more experience to its management team, and reorganized its sales and marketing activities.
	On August 22, 2013, the Company received a notice from The NASDAQ Stock Market (“NASDAQ”) that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, the Company effected a one-for-ten reverse split of its common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, the Company was notified by NASDAQ that it is now in compliance with the minimum bid price requirement.
	In July 2014, MELA announced that it took the first step in the process of obtaining insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (“MSDSLA”) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection of melanoma. The Company submitted an application for a Current Procedural Terminology (“CPT®”) code, which is necessary for Medicare Part B reimbursement by the Centers for Medicare and Medicaid Services (“CMS”). Currently, there is no CPT® code available for the MelaFind® process. The Company plans to commence efforts to obtain reimbursement from private insurers during the CMS’ coverage determination process. Coverage could become available as early as January 2016.
	MELA has experienced recurring losses and negative cash flow from operations and management expects these conditions to continue for the foreseeable future. As a result of these factors, the Company has been and continues to be dependent on raising capital from the sale of securities in order to operate and to meet its obligations in the ordinary course of business. In February 2014, the Company raised net proceeds of approximately $11.5 million from the sale of Series A convertible preferred stock and warrants to purchase common stock to strengthen the Company’s financial position (see Footnote 11 “STOCKHOLDERS’ EQUITY”). In July 2014, the Company issued Series B convertible preferred stock, senior secured convertible debt and warrants (see Footnote 9 “DEBT”). The Company raised an additional $13.8 million in net proceeds from this offering. The proceeds from the sale of the Series B convertible preferred stock were used to redeem all outstanding shares of Series A convertible preferred stock.
	The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Interim results may not be indicative of the results that may be expected for the year. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The accompanying financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has devoted substantially all of its cash resources to the development and marketing of the MelaFind® system and general and administrative expenses, and to date it has not generated any significant revenues from the sale of products. As a result, MELA has an accumulated deficit of $177,789,288 as of September 30, 2014. The Company’s recurring losses from operations and the accumulated deficit raise substantial doubt about its ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Even if the Company succeeds in commercializing the MelaFind® system it may never become profitable. The Company expects to continue to incur significant losses over the next several years.

Use_of_Estimates

Use of Estimates	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Use of Estimates	'
	2. USE OF ESTIMATES
	The preparation of financial statements in conformity with GAAP requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to inventory reserves, stock-based compensation arrangements, and the warrant liability. Actual results could differ from these estimates. Estimates of future operating results are based upon numerous factors including past experience, known information and subjective estimates and assumptions. Actual future operating results could be materially different from management’s estimates and unforeseen events could adversely affect management’s estimates.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	3. RECENT ACCOUNTING PRONOUNCEMENTS
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU” No. 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for annual periods ending after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company’s results of operations, cash flows or financial condition.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016 and interim periods within those periods. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	4. INVENTORY
	Inventories currently consist of MelaFind® systems, work in process components and other finished products and accessories that are stated at the lower of cost or market value. Inventory accessories are purchased items to be sold for use in the operation of the MelaFind® systems. The Company maintains a reserve for specific inventory items that are no longer being used in the devices.
	During the quarter ended September 30, 2014, the Company replaced the Hand-held Imager’s “Field Phantom” imaging test with the “Flap Shutter” imaging test. The new Flap Shutter test utilizes an internal imaging target within each Hand-held Imager. This new test process eliminates the need for the external Field Phantom imaging test fixture; thereby reducing manufacturing material costs, test labor and cycle time. Additionally, an improvement to the Hand-held Imager’s overall reliability is anticipated by eliminating human error associated with the previous Field Phantom imaging test process. As a result, the Phantom Fixture has become obsolete and an additional $537,774 was added to the reserve for obsolete inventory.
	In December 2013, the Company changed its business model for the MelaFind® system from a rental-based model to a sales-based model. In accordance with this new sales model, the Company reclassified $5,401,866 of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale.
	During the second quarter of 2014, the Company deferred repairs of certain of its MelaFind system units that it determined were unlikely to be sold during the next several periods. The Company estimated the cost to restore its system units to sellable condition and created a repair reserve amounting to $538,559 at September 30, 2014.
	On August 6, 2014, the Company and Askion GmbH entered into an “Amended and Restated Askion Production Agreement.” This agreement is a mutual settlement and release agreement of two prior unfulfilled purchase orders. The settlement amount of $1,142,512 was used for inventory purchases which consist primarily of Hand-held Imager assemblies.
	Inventory consists of the following:
		September 30,			December 31,
		2014			2013
	MelaFind® Systems	$	4,240,506		$	4,858,088
	Hand-held Imager assemblies		1,142,512			—
	Components		858,377			543,778
	Mela record cards		326,660			327,900
	Accessories		197,065			226,439
			6,765,120			5,956,205
	Reserve for obsolete inventory		(862,774	)		(325,000	)
	Reserve for inventory repairs		(538,559	)		—
		$	5,363,787		$	5,631,205

Property_and_Equipment_Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment, Net	'
	5. PROPERTY AND EQUIPMENT, NET
	The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An asset is considered to be impaired when its carrying amount exceeds the sum of the undiscounted future net cash flows expected to result from the use of the asset and its eventual disposition. The amount of impairment loss, if any, is measured as the difference between the net book value of the asset and its estimated fair value.
	In December 2013, the Company changed its business model for the MelaFind® system from a rental-based to a sales-based model. In accordance with this new sales model, the Company reclassified $5,401,866 of MelaFind® systems from property and equipment into inventory at December 31, 2013. The systems reclassified into inventory represent systems available for sale. Systems that have been leased under the rental-based model remain in property and equipment.
	During the nine months ended September 30, 2014, the Company reclassified $725,598 of accumulated depreciation related to MelaFind system components that were previously leased and are now available for sale that were included in inventory at December 31, 2013.
	Property and equipment, at cost, consists of the following:
		September 30,			December 31,			Estimated
		2014			2013			Useful Life
	Leasehold improvements	$	905,888		$	905,888			Lease Term
	Laboratory and research equipment		1,083,661			1,083,661			3-5 years
	Office furniture and equipment		1,969,454			2,022,833			3-5 years
	MelaFind® Systems		4,031,190			5,081,816
			7,990,193			9,094,198
	Accumulated depreciation and amortization		(5,277,110	)		(5,403,414	)
		$	2,713,083		$	3,690,784
	Depreciation expense for the three and nine months ended September 30, 2014 was $487,998 and $1,366,995, respectively, and for the three and nine months ended September 30, 2013 was $681,759 and $1,785,793, respectively.

Net_Loss_Per_Common_Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss Per Common Share	'
	6. NET LOSS PER COMMON SHARE
	Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents outstanding as of September 30, 2014 and September 30, 2013 consist of common stock equivalents of convertible preferred stock, senior secured convertible debentures, common stock purchase warrants and common stock options, which are summarized as follows:
		September 30,
		2014		2013
	Common stock equivalents of convertible preferred stock		4,795,321		—
	Common stock equivalents of convertible debentures		5,847,955		—
	Common stock purchase warrants		13,078,920		89,321
	Common stock options		320,349		255,635
	Total		24,042,545		344,956

Comprehensive_Loss

Comprehensive Loss	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Comprehensive Loss	'
	7. COMPREHENSIVE LOSS
	For all periods presented, the Company had no comprehensive income items and accordingly there is no difference between the reported net loss and per share amounts per the Statement of Operations and comprehensive net loss and related per share amounts.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	8. STOCK-BASED COMPENSATION
	Stock awards under the Company’s stock option plans have been granted with exercise prices that are no less than the market value of the stock on the date of the grant. Options granted under the 2013 and 2005 Plans are generally time-based or performance-based options and vesting varies accordingly. Options under the plans expire up to a maximum of ten years from the date of grant.
	The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:
		September 30,
		2014	2013
	Expected life	6.5 years	5.5-6.5 years
	Expected volatility	75.51-73.87%	71.71%-76.83%
	Risk-free interest rate	2.14-2.45%	.71-2.04%
	Dividend yield	—	—
	Stock-based compensation expense for the three and nine months ended September 30, 2014 was $115,180 and $447,295, respectively, and for the three and nine months ended September 30, 2013 was $159,621 and $1,256,754, respectively.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	9. DEBT
	On July 21, 2014, the Company entered into a definitive Securities Purchase Agreement (the “Purchase Agreement”) with entities affiliated with institutional investors (the “Investors”) providing for the issuance of (i) 12,300 shares of Series B convertible preferred stock, par value $0.10 and a stated value of $1,000 per share (the “Series B Preferred Stock”), (ii) Senior Secured Convertible Debentures in the aggregate principal amount of $15,000,005, due, subject to the terms therein, in July 2019 (the “Debentures”), (iii) warrants (the “July 2014 Series A Warrants”) to purchase up to an aggregate of 6,198,832 shares of common stock, $0.001 par value per share (the “Common Stock”), at an exercise price of $2.45 per share expiring in July 2019 issued to the investors in the Debentures, and (iv) warrants (the “July 2014 Series B Warrants”) to purchase up to an aggregate of 4,795,321 shares of Common Stock at an exercise price of $2.45 per share expiring in January 2016 issued to investors in the Series B Preferred Stock (the “Offering”). The Offering closed on July 24, 2014. Proceeds from the Debentures will be used for general working capital purposes.
	The Debentures bear interest at an annual rate of 4%, payable quarterly or upon conversion into shares of Common Stock. The Debentures are convertible at any time into an aggregate of 5,847,955 shares of Common Stock at an initial conversion price of $2.565 per share (which represents a price above the closing bid price of the Common Stock on July 18, 2014, the trading day immediately prior to the entry into the Purchase Agreement). The Company’s obligations under the Debentures are secured by a first priority lien on all of the Company’s intellectual property pursuant to the terms of a security agreement (“Security Agreement”) dated July 21, 2014 among the Company and the investors. The Preferred Stock is only entitled to dividends in the event that dividends are paid on the Common Stock, and the Preferred Stock will not have any preferences over the Common Stock, including liquidation rights. The warrants are also subject to certain ownership limitations and are immediately exercisable.
	In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement with the Investors pursuant to which the Company was obligated to file a registration statement to register for resale the shares of Common Stock issuable upon conversion of the Series B Preferred Stock and Debentures and upon exercise of the Warrants. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on August 19, 2014, which was declared effective by the SEC on October 20, 2014 (File No. 333-198249).
	For financial reporting purposes, the $15,000,005 funded by the Investors on July 21, 2014 was allocated first to the fair value of the obligation to issue the Warrants, which totaled $5,296,345, then to the intrinsic value of the beneficial conversion feature on the Debentures of $4,565,350 and then the balance was further reduced by the fair value of warrants issued to the placement agent for services rendered of $491,228, resulting in an initial carrying value of the Debentures of $4,647,082. The initial debt discount on the Debentures totaled $10,352,923 and will be amortized over the five year life of the Debentures. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligations, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. The fair value of the warrant obligation was determined using an option pricing model that used various assumptions including: a stock price of $2.44 per share, volatility of 93.46%, time to maturity of 5.0 years, exercise price of $2.45 per share and a risk free interest rate of return of 1.62%.
	On March 15, 2013, the Company executed loan documents with Hercules Technology Growth Capital Inc. (“Hercules”), a venture capital lender, whereby the Company borrowed $6,000,000 (the “Loan”). The Loan accrued interest at a rate of 10.45%. The term of the Loan was 42 months with interest payments only during the first 12 months. On September 10, 2013, the Company elected to prepay the Loan and paid Hercules $6,400,000, including the end of term fee of $425,000, to settle all obligations to Hercules. Hercules agreed to waive the prepayment penalty of $180,000.
	Upon executing the loan documents on March 15, 2013, the Company became obligated to issue to the Lender a warrant to purchase shares of the Company’s common stock upon approval by the Company’s stockholders of a proposal to increase the Company’s number of authorized shares of common stock at its 2013 Annual Meeting of Stockholders. The number of shares that could be acquired upon exercise of the warrant and the exercise price per share were not fixed on March 15, 2013, but would be determined when the warrant was issued based on a defined formula using trading prices of the Company’s common stock during certain periods prior to the issuance of the warrant. The Company’s stockholders approved the increase in the number of authorized shares of common stock on April 25, 2013 and on April 26, 2013 the warrant was issued to the Lender. The terms of the warrant were fixed on the date of issuance whereby the Lender received a warrant to purchase 69,321 shares of common stock at an exercise price of approximately $11.20 per share. The warrant expires on April 26, 2018.
	For financial reporting purposes, the $6,000,000 funded by the Lender on March 15, 2013 was allocated first to the fair value of the obligation to issue the warrant, which totaled approximately $563,000, and the balance was reduced further by the Lender’s costs and fees, resulting in an initial carrying value of the loan of approximately $5,300,000. The Company used a Level 3 fair value measurement to determine fair value of the warrant obligation, which has significant unobservable inputs as defined in Accounting Standards Codification 820 “Fair Value Measures”. During the period from the loan inception date until the warrant obligation was fulfilled and the warrant was issued, the warrant obligation was reflected as a long-term liability at fair value. Changes in the fair value (“mark-to-market adjustments”) of the warrant obligation of $89,859 are included in operating results for the nine months ended September 30, 2013. The fair value of the warrant obligation was determined using the Monte Carlo pricing model that used various assumptions that included: stock prices ranging from $11.60 to $11.80 per share, volatility of 77%, time to maturity of 5 years, exercise prices ranging from $11.50 to $11.60 and a risk free interest rate of return of .84%. Under the Monte Carlo model, a 10% change in the underlying unobservable inputs would not have a significant impact on the fair value.
	The value of the warrant obligation combined with the costs resulted in an initial loan discount of approximately $727,000. The terms of the Loan required us to pay the Lender a fee of $425,000 at the maturity of the Loan. The loan discount and the fee were being amortized as additional interest expense over the life of the loan using the interest method. As discussed above, prior to the terms of the warrant being fixed on April 26, 2013, the warrant obligation fell within the scope of Accounting Standards Codification 815 “Derivatives and Hedging” (“ASC 815”) and therefore the warrant obligation was accounted for as a derivative reflected as a long-term liability until the warrant was issued on April 26, 2013. The terms of the warrant upon issuance no longer required derivative accounting under ASC 815 and therefore the fair value of the warrant was classified within stockholders’ equity.
	As the result of the Company electing to prepay the loan on September 10, 2013, the unamortized loan discount, fee and deferred financing costs that were expensed at that date were $983,330.

Reverse_Split_of_Common_Stock

Reverse Split of Common Stock	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Reverse Split of Common Stock	'
	10. REVERSE SPLIT OF COMMON STOCK
	On July 9, 2014, the Company effected a previously authorized 1-for-10 reverse stock split of its common stock. The reverse split took effect at the start of trading on July 10, 2014 on a 1-for-10 split basis. All prior periods have been retroactively adjusted to reflect the reverse stock split. The par value of the common stock did not change.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Stockholders' Equity	'
	11. STOCKHOLDERS’ EQUITY
	Preferred Stock
	The Company is authorized to issue 10,000,000 shares of preferred stock with a par value of $0.10 per share with such designation, rights and preferences as may be determined from time to time by the Company’s Board of Directors.
	On July 24, 2014, in connection with the Offering (see Note 9 “DEBT”), the Company issued to certain investors 12,300 shares of Series B Convertible Preferred Stock at a price of $1,000 per share convertible into Common Stock at an initial price of $2.565 per share and Series B Warrants to purchase up to an aggregate of 4,795,321 shares of Common Stock at an exercise price of $2.45 per share, expiring in January 2016. The Preferred Stock is convertible into an aggregate of 4,795,321 shares of Common Stock. Holders of the Preferred Stock are entitled to dividends only in the event that dividends are paid on the Common Stock, and the Preferred Stock has no preferences over the Common Stock, including liquidation rights. The Preferred Stock and the July 2014 Series A Warrants are immediately exercisable and are subject to certain ownership limitations.
	For financial reporting purposes, the $12,300,000 preferred stock value was allocated first to the fair value of the July 2014 Series B warrants, which totaled $2,486,780, then to the intrinsic value of the beneficial conversion feature of $1,887,364. The amount of the beneficial conversion feature is considered to be a deemed dividend on the date of issuance to the Series B preferred stockholders due to the July 2014 Series B warrants being immediately exercisable. The deemed dividend was accounted for as a movement within additional paid-in capital. The following table represents the net loss attributable to common stockholders after giving effect for the deemed dividend:
		Three months ended			Nine months ended
		September 30, 2014			September 30, 2014
	Net loss	$	(2,287,862	)	$	(9,641,410	)
	Series B preferred stock beneficial conversion feature		(1,887,364	)		(1,887,364	)
	Net loss attributable to common stockholders	$	(4,175,226	)	$	(11,528,774	)
	Basic and diluted net loss per common share	$	(0.80	)	$	(2.26	)
	Basic and diluted weighted average number of commons shares outstanding		5,216,290			5,108,418
	Pursuant to the terms of the Purchase Agreement, the Series A Convertible Preferred Stock was redeemed from the proceeds of the Series B Convertible Preferred Stock. In September 2014, the Company amended the registration statement related to the Series A Preferred Stock to deregister those shares that would have been issuable upon conversion of the Series A Preferred Stock had it not already been redeemed by the proceeds of the Series B Preferred Stock.
	On February 5, 2014, pursuant to a securities purchase agreement, dated as of January 31, 2014, the Company sold to the Purchasers (i) an aggregate of 12,300 shares of Series A Convertible Preferred Stock, par value $0.10 and a stated value of $1,000 per share (the “Series A Preferred Stock”), convertible into 1,464,287 shares of common stock at an initial conversion price of $8.40, and (ii) warrants to purchase up to 1,329,731 shares of common stock for net proceeds of $11,457,831. The warrants have an exercise price of $7.40 per share, are immediately exercisable and have a term of five years. These warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative liability and recorded at fair value on the inception date of February 5, 2014. They will be recorded at their respective fair value at each subsequent balance sheet date. The fair value of these warrants on September 30, 2014 was approximately $957,406. The change in fair value of these warrants for the three and nine months ended September 30, 2014 was a benefit of $1,436,107 and $4,627,459, respectively (see footnote 12 “FAIR VALUE OF FINANCIAL INSTRUMENTS”).
	In connection with this financing, the Company also granted to the Purchasers resale registration rights with respect to the shares of common stock underlying the Series A Preferred Stock and the warrants pursuant to the terms of a Registration Rights Agreement. The Purchasers were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, effectiveness and maintaining an effective registration statement covering the shares underlying the Series A Preferred Stock and the warrants. The Company was unable to meet certain filing and effectiveness requirements and as a result paid liquidated damages to the Purchasers in the aggregate amount of $3,419,698. Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.
	On July 21, 2014, the Company entered into the Purchase Agreement and issued, among other things, the Series B Preferred Stock (See Footnote 9 “DEBT”). In connection with the issuance of the Series B Preferred Stock, the Company redeemed all 12,300 shares of Series A Preferred Stock. In September 2014, the Company amended the registration statement related to the Series A Preferred Stock (File No. 333-194649) to deregister those shares that would have been issuable upon conversion of the Series A Preferred Stock.
	Common Stock
	The Company is authorized to issue 50,000,000 shares of common stock with a par value of $0.001 per share.
	On October 29, 2013, the Company entered into a securities purchase agreement with certain accredited investors in connection with a $6,000,000 registered offering of 422,819 shares of the Company’s common stock, fully paid prefunded Series B Warrants to purchase up to 434,325 shares of its common stock and additional warrants (“October 2013 Series A Warrants”) to purchase up to 685,715 shares of its common stock. The October 2013 Series A Warrants are exercisable beginning on May 1, 2014 at a price of $8.50 per share and expire on May 1, 2019. The prefunded Series B Warrants are exercisable immediately for no additional consideration. The offering closed on October 31, 2013.
	The holders exercised all of the prefunded Series B warrants in March 2014. There were no warrant exercises in the first nine months of 2013.
	The October 2013 Series A Warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon a change in control of the Company and therefore are classified as a derivative. Therefore, these warrants have been recorded at fair value at the inception date of October 31, 2013, and will be recorded at their respective fair values at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as a non-operating, non-cash charge in the Statements of Operations. The fair value of these warrants on September 30, 2014 was approximately $493,715. The change in fair value of these warrants for the three and nine months ended September 30, 2014, was a benefit of $671,999 and $2,523,427, respectively (see footnote 12 “FAIR VALUE OF FINANCIAL INSTRUMENTS”).
	On August 22, 2013, the Company received a notice from NASDAQ that, for the previous 30 consecutive business days, the Company was not in compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ Capital Market. In July 2014, the Company effected a one-for-ten reverse split of its common stock in order to regain compliance with the minimum bid price requirement prior to the expiration of the last applicable grace period. On July 24, 2014, the Company was notified by NASDAQ that it is now in compliance with the minimum bid price requirement.
	Outstanding common stock warrants consist of the following:
	Issue Date	Expiration Date			Total			Ex. Price
					Warrants
	4/26/2013		4/26/18			69,321		$	11.18
	10/31/13		4/30/19			685,715		$	8.5
	2/5/2014		2/5/19			1,329,731		$	7.4
	7/24/2014		7/24/19			6,198,832		$	2.45
	7/24/2014		1/24/16			4,795,321		$	2.45
						13,078,920
	During the three months ended September 30, 2014, the number of outstanding shares of the Company’s common stock increased from 5,213,969 to 5,217,742.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	12. FAIR VALUE OF FINANCIAL INSTRUMENTS
	Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value for applicable assets and liabilities, we consider the principal or most advantageous market in which we would transact and we consider assumptions market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. This guidance also establishes a fair value hierarchy to prioritize inputs used in measuring fair value as follows:
		•		Level 1: Observable inputs such as quoted prices in active markets;
		•		Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
		•		Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
	The Company’s financial instruments are cash and cash equivalents, accounts payable, and derivative warrant liabilities. The recorded values of cash equivalents and accounts payable approximate their fair values based on their short-term nature. The fair value of derivative warrant liabilities is estimated using option pricing models that are based on the individual characteristics of our warrants, preferred and common stock, the derivative warrant liability on the valuation date as well as assumptions for volatility, remaining expected life, risk-free interest rate and, in some cases, credit spread. The derivative warrant liabilities are the only recurring Level 3 fair value measures.
	The warrants have non-standard terms as they relate to a fundamental transaction and require a net-cash settlement upon change in control of the Company and therefore are classified as a derivative. These warrants have been recorded at their fair value using an option pricing model and will be recorded at their respective fair value at each subsequent balance sheet date.
	A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of September 30, 2014 and December 31, 2013 is as follows:
			September 30, 2014			December 31, 2013
	Stock Price		$	1.72		$	6.4
	Risk-free Rate (5-year U.S. Treasury Yield)			1.76	%		1.75	%
	Volatility (Annual)			93.46	%		93.43	%
	Time to Maturity (Years)			4.35-4.58			5.33
	Derivative warrant liabilities consist of the following:
			Fair Value
			Measurements Using
			Significant
			Unobservable Inputs
			(Level 3)
	Beginning balance at January 1, 2014		$	3,017,142
	Issuance of warrants in February 2014			5,584,865
	Changes in estimated fair value			(7,150,886	)
	Ending balance at September 30, 2014		$	1,451,121

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	13. SUBSEQUENT EVENTS
	In October 2014, 513 shares of Convertible Preferred Stock were converted into 200,000 shares of common stock, and $1,588,992 of Convertible Debentures were converted into 619,490 shares of common stock.

Recent_Accounting_Pronouncemen1

Recent Accounting Pronouncements (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update “ASU” No. 2014-15 on “Presentation of Financial Statements Going Concern (Subtopic 205-40) – Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. Currently, there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. In doing so, the amendments are intended to reduce diversity in the timing and content of footnote disclosures. The amendments require management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management’s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management’s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in this update are effective for annual periods ending after December 15, 2016. Early adoption is permitted. The Company is currently evaluating the new guidance to determine the impact the adoption of this guidance will have on the Company’s results of operations, cash flows or financial condition.
	In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606).” ASU 2014-09 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The new model will require revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services. ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2016 and interim periods within those periods. Early adoption is not permitted. Companies may use either a full retrospective or a modified retrospective approach to adopt ASU 2014-09. The Company is currently assessing the impact that adopting this new accounting guidance will have on its consolidated financial statements and footnote disclosures.

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	Inventory consists of the following:
		September 30,			December 31,
		2014			2013
	MelaFind® Systems	$	4,240,506		$	4,858,088
	Hand-held Imager assemblies		1,142,512			—
	Components		858,377			543,778
	Mela record cards		326,660			327,900
	Accessories		197,065			226,439
			6,765,120			5,956,205
	Reserve for obsolete inventory		(862,774	)		(325,000	)
	Reserve for inventory repairs		(538,559	)		—
		$	5,363,787		$	5,631,205

Property_and_Equipment_Net_Tab

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment, at cost, consists of the following:
		September 30,			December 31,			Estimated
		2014			2013			Useful Life
	Leasehold improvements	$	905,888		$	905,888			Lease Term
	Laboratory and research equipment		1,083,661			1,083,661			3-5 years
	Office furniture and equipment		1,969,454			2,022,833			3-5 years
	MelaFind® Systems		4,031,190			5,081,816
			7,990,193			9,094,198
	Accumulated depreciation and amortization		(5,277,110	)		(5,403,414	)
		$	2,713,083		$	3,690,784

Net_Loss_Per_Common_Share_Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Common Stock Equivalents of Convertible Preferred Stock, Senior Secured Convertible Debentures, Common Stock Purchase Warrants and Common Stock Options	'
	Potential common stock equivalents outstanding as of September 30, 2014 and September 30, 2013 consist of common stock equivalents of convertible preferred stock, senior secured convertible debentures, common stock purchase warrants and common stock options, which are summarized as follows:
		September 30,
		2014		2013
	Common stock equivalents of convertible preferred stock		4,795,321		—
	Common stock equivalents of convertible debentures		5,847,955		—
	Common stock purchase warrants		13,078,920		89,321
	Common stock options		320,349		255,635
	Total		24,042,545		344,956

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Fair Value of Each Option Award Granted	'
	The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:
		September 30,
		2014	2013
	Expected life	6.5 years	5.5-6.5 years
	Expected volatility	75.51-73.87%	71.71%-76.83%
	Risk-free interest rate	2.14-2.45%	.71-2.04%
	Dividend yield	—	—

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of Net Loss Attributable to Common Stockholders After Giving Effect for Deemed Dividend	'
	The following table represents the net loss attributable to common stockholders after giving effect for the deemed dividend:
		Three months ended			Nine months ended
		September 30, 2014			September 30, 2014
	Net loss	$	(2,287,862	)	$	(9,641,410	)
	Series B preferred stock beneficial conversion feature		(1,887,364	)		(1,887,364	)
	Net loss attributable to common stockholders	$	(4,175,226	)	$	(11,528,774	)
	Basic and diluted net loss per common share	$	(0.80	)	$	(2.26	)
	Basic and diluted weighted average number of commons shares outstanding		5,216,290			5,108,418
Schedule of Outstanding Common Stock Warrants	'
	Outstanding common stock warrants consist of the following:
	Issue Date	Expiration Date			Total			Ex. Price
					Warrants
	4/26/2013		4/26/18			69,321		$	11.18
	10/31/13		4/30/19			685,715		$	8.5
	2/5/2014		2/5/19			1,329,731		$	7.4
	7/24/2014		7/24/19			6,198,832		$	2.45
	7/24/2014		1/24/16			4,795,321		$	2.45
						13,078,920

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value Hierarchy	'
	A summary of quantitative information with respect to the valuation methodology and significant unobservable inputs used for the Company’s warrant liabilities that are categorized within Level 3 of the fair value hierarchy as of September 30, 2014 and December 31, 2013 is as follows:
		September 30, 2014			December 31, 2013
	Stock Price	$	1.72		$	6.4
	Risk-free Rate (5-year U.S. Treasury Yield)		1.76	%		1.75	%
	Volatility (Annual)		93.46	%		93.43	%
	Time to Maturity (Years)		4.35-4.58			5.33
Schedule of Derivative Warrant Liabilities	'
	Derivative warrant liabilities consist of the following:
		Fair Value
		Measurements Using
		Significant
		Unobservable Inputs
		(Level 3)
	Beginning balance at January 1, 2014	$	3,017,142
	Issuance of warrants in February 2014		5,584,865
	Changes in estimated fair value		(7,150,886	)
	Ending balance at September 30, 2014	$	1,451,121

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation - Additional Information (Detail) (USD $)	0 Months Ended		1 Months Ended		9 Months Ended
	Jul. 09, 2014	Aug. 22, 2013	Jul. 31, 2014	Feb. 28, 2014	Sep. 30, 2014	Dec. 31, 2013		Aug. 22, 2013
Accounting Policies [Abstract]	'	'	'	'	'	'		'
Number of consecutive business days, non-compliance of minimum bid price	'	'30 days	'	'	'	'		'
Minimum bid price	'	'	'	'	'	'		$1
Reverse stock split, common stock	'	'	'	'	'In July 2014, the Company effected a one-for-ten reverse split of its common stock	'		'
Reverse stock split ratio, common stock	0.1	'	'	'	'	'		'
Proceeds from sale of Series A convertible preferred stock and warrants	'	'	'	$11,500,000	'	'		'
Net proceeds from offering of Series B convertible preferred stock, senior secured convertible debt and warrants	'	'	13,800,000	'	'	'		'
Accumulated deficit	'	'	'	'	$177,789,288	$168,147,878	[1]	'
[1]	Derived from the audited balance sheet as of December 31, 2013

Inventory_Additional_Informati

Inventory - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

Aug. 06, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Aug. 06, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Sep. 30, 2014

PurchaseOrder

Hand-held Imager Assemblies [Member]

Hand-held Imager Assemblies [Member]

Obsolete Inventory [Member]

Obsolete Inventory [Member]

MelaFind Systems [Member]

MelaFind Systems [Member]

MelaFind Systems [Member]

Inventory Repairs [Member]

Components [Member]

Inventory [Line Items]

'

'

'

'

'

'

'

'

'

'

'

Additions to reserve

'

'

'

'

'

$537,774

'

'

'

'

'

Inventory, Gross

'

6,765,120

5,956,205

1,142,512

'

'

'

4,240,506

4,858,088

5,401,866

'

Reserve for inventory

'

1,401,333

325,000

[1]

'

'

862,774

325,000

'

'

'

538,559

Settlement amount

'

'

'

'

$1,142,512

'

'

'

'

'

'

Number of unfulfilled purchase orders

2

'

'

'

'

'

'

'

'

'

'

[1]

Derived from the audited balance sheet as of December 31, 2013

Inventory_Schedule_of_Inventor

Inventory - Schedule of Inventory (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory [Line Items]	'	'
Inventory, Gross	$6,765,120	$5,956,205
Reserve for inventory	-1,401,333	-325,000	[1]
Inventory, Net	5,363,787	5,631,205	[1]
MelaFind Systems [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	4,240,506	4,858,088
Hand-held Imager Assemblies [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	1,142,512	'
Components [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	858,377	543,778
Mela Record Cards [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	326,660	327,900
Accessories [Member]	'	'
Inventory [Line Items]	'	'
Inventory, Gross	197,065	226,439
Obsolete Inventory [Member]	'	'
Inventory [Line Items]	'	'
Reserve for inventory	-862,774	-325,000
Inventory Repairs [Member]	'	'
Inventory [Line Items]	'	'
Reserve for inventory	($538,559)	'
[1]	Derived from the audited balance sheet as of December 31, 2013

Property_and_Equipment_Net_Add

Property and Equipment, Net - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Inventory, Gross	$6,765,120	'	$6,765,120	'	$5,956,205
Accumulated depreciation	5,277,110	'	5,277,110	'	5,403,414
Depreciation expense	487,998	681,759	1,366,995	1,785,793	'
MelaFind Systems [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Inventory, Gross	4,240,506	'	4,240,506	'	4,858,088
Accumulated depreciation	725,598	'	725,598	'	'
MelaFind Systems [Member] | Components [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Inventory, Gross	'	'	'	'	$5,401,866

Property_and_Equipment_Net_Sum

Property and Equipment, Net - Summary of Property and Equipment (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Gross	$7,990,193	$9,094,198
Accumulated depreciation and amortization	-5,277,110	-5,403,414
Net	2,713,083	3,690,784	[1]
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	905,888	905,888
Estimated Useful Life	'Lease Term	'
Laboratory and Research Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	1,083,661	1,083,661
Estimated Useful Life	'3-5 years	'
Office Furniture and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	1,969,454	2,022,833
Estimated Useful Life	'3-5 years	'
MelaFind Systems [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Gross	$4,031,190	$5,081,816
[1]	Derived from the audited balance sheet as of December 31, 2013

Net_Loss_Per_Common_Share_Sche

Net Loss Per Common Share - Schedule of Common Stock Equivalents of Convertible Preferred Stock, Senior Secured Convertible Debentures, Common Stock Purchase Warrants and Common Stock Options (Detail)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	24,042,545	344,956
Series B warrants [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	13,078,920	89,321
Common Stock Equivalents of Convertible Preferred Stock [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	4,795,321	'
Common Stock Equivalents of Convertible Debentures [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	5,847,955	'
Common Stock Options [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Potential common stock equivalents	320,349	255,635

Comprehensive_Loss_Additional_

Comprehensive Loss - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Net Income (Loss) Attributable to Parent [Abstract]	'	'
Comprehensive income (loss)	$0	$0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$115,180	$159,621	$447,295	$1,256,754
Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expiry period of option plans	'	'	'10 years	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Fair Value of Each Option Award Granted (Detail)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life	'6 years 6 months	'
Expected volatility - Minimum	75.51%	71.71%
Expected volatility - Maximum	73.87%	76.83%
Risk-free interest rate - Minimum	2.14%	0.71%
Risk-free interest rate - Maximum	2.45%	2.04%
Dividend yield	'	'
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life	'	'5 years 6 months
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life	'	'6 years 6 months

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

Jul. 24, 2014

Jul. 21, 2014

Sep. 10, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Jul. 21, 2014

Mar. 15, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jul. 21, 2014

Jul. 21, 2014

Jul. 21, 2014

Sep. 30, 2014

Jul. 21, 2014

Jul. 21, 2014

Oct. 29, 2013

Jul. 24, 2014

Jul. 21, 2014

Jul. 24, 2014

Jul. 21, 2014

Oct. 29, 2013

Mar. 15, 2013

Sep. 30, 2014

Sep. 10, 2013

Mar. 15, 2013

Minimum [Member]

Maximum [Member]

Warrant Obligation [Member]

Warrant Obligation [Member]

Warrant Obligation [Member]

Warrant Obligation [Member]

Debentures [Member]

Debentures [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Option Pricing Model [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Hercules Technology Growth Capital Inc. [Member]

Hercules Technology Growth Capital Inc. [Member]

Hercules Technology Growth Capital Inc. [Member]

Hercules Technology Growth Capital Inc. [Member]

Minimum [Member]

Maximum [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

'

$0.10

$0.10

$0.10

[1]

'

'

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock stated value, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior Secured Convertible Debentures, amount

'

$15,000,005

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,198,832

'

'

'

4,795,321

4,795,321

'

'

'

'

'

Common stock, stated value per share

'

'

'

$0.00

$0.00

$0.00

[1]

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.45

$8.50

'

'

$2.45

$2.45

'

'

'

'

$11.20

Warrant expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2019-07

'

'

'2016-01

'2016-07

'

'

'

'

'

'

'

Closing date of offering

24-Jul-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.45%

Debentures converted to common stock

'

5,847,955

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock converted to common stock, conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.56

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan terms and security agreement date

'

21-Jul-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrant obligation

'

'

'

'

'

'

5,296,345

563,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Security agreement date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

21-Jul-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of beneficial conversion feature on Debentures

'

4,565,350

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value of Warrants issued to the placement agent for services rendered

'

'

'

'

'

'

491,228

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial carrying value of Debentures

'

'

'

'

'

'

4,647,082

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial loan discount

'

'

'

727,000

727,000

'

'

'

'

'

'

'

'

'

'

10,352,923

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization period of Debentures

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock prices

'

'

'

'

'

'

'

'

'

'

'

'

$11.60

$11.80

'

'

'

'

$2.44

'

'

'

'

'

'

'

'

'

'

'

'

Volatility

'

'

'

'

93.46%

93.43%

'

'

'

'

77.00%

'

'

'

'

'

'

'

93.46%

'

'

'

'

'

'

'

'

'

'

'

'

Maturity period

'

'

'

'

'

'5 years 3 months 29 days

'

'

'4 years 4 months 6 days

'4 years 6 months 29 days

'5 years

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

Exercise prices

'

'

'

$1.72

$1.72

$6.40

'

'

'

'

'

'

$11.50

$11.60

'

'

'

'

$2.45

'

'

'

'

'

'

'

'

'

'

'

'

Risk free interest rate of return

'

'

'

'

1.76%

1.75%

'

'

'

'

0.84%

'

'

'

'

'

'

'

1.62%

'

'

'

'

'

'

'

'

'

'

'

'

Loan payable

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,000,000

Maturity period of loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'42 months

'

'

'

Time period of interest payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'First 12 months

'

'

Prepayment of loan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,400,000

'

Term fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

425,000

'

Prepayment penalty

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

180,000

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

685,715

'

'

'

'

434,325

'

'

'

69,321

Expiry date for warrant outstanding

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26-Apr-18

'

'

Warrant issuance date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

26-Apr-13

'

'

Initial carrying value of the loan

'

'

'

'

'

'

'

5,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Changes in fair value of warrants

'

'

'

-671,999

-2,523,427

'

'

'

'

'

'

89,859

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in underlying unobservable inputs

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on early extinguishment of debt

'

'

$983,330

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Derived from the audited balance sheet as of December 31, 2013

Reverse_Split_of_Common_Stock_

Reverse Split of Common Stock - Additional Information (Detail)	0 Months Ended	9 Months Ended
	Jul. 09, 2014	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Reverse stock split, common stock	'	'In July 2014, the Company effected a one-for-ten reverse split of its common stock
Reverse stock split ratio, common stock	0.1	'
Reverse stock split, effective date	10-Jul-14	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

0 Months Ended

9 Months Ended

Jul. 09, 2014

Apr. 03, 2014

Aug. 22, 2013

Sep. 30, 2014

Sep. 30, 2014

Jul. 21, 2014

Jun. 30, 2014

Dec. 31, 2013

Oct. 29, 2013

Aug. 22, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jul. 21, 2014

Feb. 05, 2014

Feb. 05, 2014

Jul. 24, 2014

Jul. 24, 2014

Jul. 21, 2014

Sep. 30, 2014

Jul. 24, 2014

Jul. 21, 2014

Jul. 24, 2014

Jul. 21, 2014

Jul. 24, 2014

Jul. 21, 2014

Oct. 29, 2013

Sep. 30, 2013

Jul. 21, 2014

Oct. 29, 2013

Sep. 30, 2014

Jul. 21, 2014

Oct. 29, 2013

Securities Purchase Agreement [Member]

Series B warrants [Member]

Series B warrants [Member]

Common Stock Equivalents of Convertible Preferred Stock [Member]

Common Stock Equivalents of Convertible Preferred Stock [Member]

Common Stock Equivalents of Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Convertible Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series B Prefunded Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B [Member]

Series B [Member]

Securities Financing Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares authorized

'

'

'

10,000,000

10,000,000

'

'

10,000,000

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

'

$0.10

$0.10

'

'

$0.10

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares issued

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12,300

'

12,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock stated value, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1,000

'

$1,000

'

'

'

$1,000

'

'

'

'

'

'

'

'

'

'

'

Preferred stock converted to common stock, conversion price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$8.40

'

$2.56

'

'

'

$2.56

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,329,731

'

'

'

'

'

'

'

'

4,795,321

4,795,321

'

'

'

'

'

6,198,832

'

Warrants issued to purchase common stock, exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$7.40

'

'

'

'

'

'

'

'

$2.45

$2.45

'

'

'

'

'

$2.45

$8.50

Warrant expiration period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2016-01

'2016-07

'

'

'

'

'2019-07

'

'

'

'

Preferred stock converted to common stock, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,464,287

'

'

'

'

4,795,321

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock value allocated

'

'

'

$1,230

$1,230

'

'

'

'

'

'

$12,300,000

$12,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total preferred stock value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,486,780

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock allocated to intrinsic value of beneficial conversion

'

'

'

'

1,887,364

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares issued

'

'

'

12,300

12,300

'

'

0

[1]

'

'

'

'

'

'

'

12,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, par value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from issuance of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,457,831

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued, exercisable term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative fair value inception date

'

'

'

'

5-Feb-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of warrants

'

'

'

493,715

493,715

'

'

'

'

'

'

957,406

957,406

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Change in fair value of warrants, benefit

'

'

'

671,999

2,523,427

'

'

'

'

'

'

1,436,107

4,627,459

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Liquidated damages paid

'

'

'

'

3,419,698

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Registration Rights Agreement description

'

'

'

'

'Under the terms of the Registration Rights Agreement, the Company filed a registration statement on March 18, 2014, which was declared effective by the SEC on April 3, 2014. Should this registration statement cease to remain effective for more than ten consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period, the Company would be subject to additional liquidated damages of up to approximately $500,000.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional liquidated damages payable

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock redeemed, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

12,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized

'

'

'

50,000,000

50,000,000

'

'

50,000,000

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, par value

'

'

'

$0.00

$0.00

$0.00

'

$0.00

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued

'

'

'

5,217,742

5,217,742

'

'

4,750,160

[1]

422,819

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

434,325

'

'

'

'

'

685,715

Proceeds from issuance of common stock and warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$6,000,000

'

'

'

Warrants exercisable date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-May-14

'

'

Warrants expiry date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1-May-19

'

'

Offering closed date

'

'

'

'

'

'

'

'

'

'

31-Oct-13

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercised

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

Number of consecutive business days, non-compliance of minimum bid price

'

'

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum bid price

'

'

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split, description

'

'

'

'

'In July 2014, the Company effected a one-for-ten reverse split of its common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse stock split ratio, common stock

0.1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock outstanding

'

'

'

5,217,742

5,217,742

'

5,213,969

4,750,160

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Derived from the audited balance sheet as of December 31, 2013

Stockholders_Equity_Schedule_o

Stockholders' Equity - Schedule of Net Loss Attributable To Common Stockholders After Giving Effect For Deemed Dividend (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Net loss	($2,287,862)	($7,404,427)	($9,641,410)	($21,337,798)
Net loss attributable to common stockholders	-4,175,226	'	-11,528,774	'
Basic and diluted net loss per common share	($0.80)	'	($2.26)	'
Basic and diluted weighted average number of commons shares outstanding	5,216,290	'	5,108,418	'
Series B Preferred Stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Series B preferred stock beneficial conversion feature	($1,887,364)	'	($1,887,364)	'

Stockholders_Equity_Schedule_o1

Stockholders' Equity - Schedule of Outstanding Common Stock Warrants (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Class of Warrant or Right [Line Items]	'
Total Warrants	13,078,920
Ex. Price $ 11.18 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	26-Apr-13
Expiration Date	26-Apr-18
Total Warrants	69,321
Ex. Price	$11.18
Ex. Price $ 8.50 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	31-Oct-13
Expiration Date	30-Apr-19
Total Warrants	685,715
Ex. Price	$8.50
Ex. Price $ 7.40 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	5-Feb-14
Expiration Date	5-Feb-19
Total Warrants	1,329,731
Ex. Price	$7.40
Ex. Price $ 2.45 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	24-Jul-14
Expiration Date	24-Jul-19
Total Warrants	6,198,832
Ex. Price	$2.45
Ex. Price $ 2.45 [Member]	'
Class of Warrant or Right [Line Items]	'
Issue Date	24-Jul-14
Expiration Date	24-Jan-16
Total Warrants	4,795,321
Ex. Price	$2.45

Fair_Value_of_Financial_Instru2

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Stock Price	$1.72	$6.40
Risk-free Rate	1.76%	1.75%
Volatility (Annual)	93.46%	93.43%
Time to Maturity (Years)	'	'5 years 3 months 29 days
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Time to Maturity (Years)	'4 years 4 months 6 days	'
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Time to Maturity (Years)	'4 years 6 months 29 days	'

Fair_Value_of_Financial_Instru3

Fair Value of Financial Instruments - Schedule of Fair Value Hierarchy (Parenthetical) (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'	'
U.S Treasury Yield, period	'5 years	'5 years

Fair_Value_of_Financial_Instru4

Fair Value of Financial Instruments - Schedule of Derivative Warrant Liabilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013		Sep. 30, 2014	Sep. 30, 2014
				Significant Unobservable Inputs (Level 3) [Member]	Significant Unobservable Inputs (Level 3) [Member]
					Series B warrants [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'		'	'
Beginning balance at January 1, 2014	$1,451,121	$3,017,142	[1]	$3,017,142	'
Issuance of warrants in February 2014	'	'		'	5,584,865
Changes in estimated fair value	'	'		-7,150,886	'
Ending balance at September 30, 2014	$1,451,121	$3,017,142	[1]	$1,451,121	'
[1]	Derived from the audited balance sheet as of December 31, 2013

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (Subsequent Event [Member], USD $)	1 Months Ended
	Oct. 31, 2014
Convertible Preferred Stock [Member]	'
Subsequent Event [Line Items]	'
Convertible Preferred Stock	513
Conversion to common stock, shares	200,000
Convertible Debentures [Member]	'
Subsequent Event [Line Items]	'
Conversion to common stock, shares	619,490
Convertible Debentures	1,588,992